Semisynthetic water-soluble derivative of rebeccamycin. Antitumor antibiotic. Topoisomerase II inhibitor. DNA intercalating agent.
Product Details
| Alternative Name: | 6-N-[2-(Diethylamino)ethyl]rebeccamycin, NSC 655649, BMY-27557-14, BMS-181176, XL 119 |
| |
| Formula: | C33H34Cl2N4O7 |
| |
| MW: | 669.6 |
| |
| Source: | Semisynthetic. |
| |
| CAS: | 119673-08-4 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Identity: | Determined by 1H-NMR. |
| |
| Appearance: | Yellow solid. |
| |
| Solubility: | Soluble in water (pH-dependent) or DMSO. |
| |
| Shipping: | Ambient Temperature |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored at -20°C. |
| |
| Handling: | After reconstitution protect from light at -20°C. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells: O.V. Denisova, et al.; Sci. Rep.
12, 13796 (2022),
Abstract;
Becatecarin (Helsinn Healthcare): G.W. Rewcastle; IDrugs
8, 838 (2005),
Abstract;
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors: A.D. Ricart, et al.; Clin. Cancer Res.
11, 8728 (2005),
Abstract;
Full Text
Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles: B.H. Long, et al.; Curr. Med. Chem. Anticancer Agents
2, 255 (2002),
Abstract;
Water soluble derivatives of rebeccamycin: T. Kaneko, et al.; J. Antibiot.
43, 125 (1990),
Abstract;
